# First patient receives partial epigenetic reprogramming for glaucoma

2026-08-15T22:52:55+00:00 | Health & Science | Indian Opinion Desk

Corroboration: 1 independent outlet

In June, a patient in the United States became the first person to receive ER 100, an experimental therapy that uses partial epigenetic reprogramming. The treatment is being tested for age-related optic nerve diseases, including glaucoma, and marks the first human trial of an approach that aims to make aged cells behave more youthfully. The therapy involves controlled expression of three transcription factors, OCT4, SOX2 and KLF4, to restore youthful patterns of gene expression. The trial is currently limited to specific cells in the eye. Whether the therapy proves safe and effective remains unknown. The development comes as researchers increasingly focus on healthspan, how long people remain healthy and capable, rather than merely extending lifespan. Cellular rejuvenation has moved from laboratory research into human testing, though the approach remains experimental.

## Coverage

- deccanherald.com <https://www.deccanherald.com/opinion/the-anatomy-of-wellness-4112789>

This story was synthesised by AI from the source linked above.

Tags: epigenetic reprogramming, ER100, glaucoma, United States
Canonical: https://indianopinion.org/first-patient-receives-partial-epigenetic-reprogramming-for-glaucoma/
License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources.
Cite: https://indianopinion.org/first-patient-receives-partial-epigenetic-reprogramming-for-glaucoma/#story-in-brief

Review state: restored archive article, accurate at time of publication, not offered to search indexes.

How this brief was made: an AI model read the report linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/